![]() |
Volumn 29, Issue 1-2, 1997, Pages 728-732
|
CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftmen but cyclosporine A is still required to reduce GVHD and morbidity
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CD34 ANTIGEN;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN A;
ADOLESCENT;
ADULT;
ANTIGEN PURIFICATION;
BONE MARROW TRANSPLANTATION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOSE RESPONSE;
DOSE TIME EFFECT RELATION;
GRAFT FAILURE;
GRAFT VERSUS HOST REACTION;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
HYPERTENSION;
IMMUNOMODULATION;
NEPHROTOXICITY;
NEUROTOXICITY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
|
EID: 0030944194
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(96)00442-3 Document Type: Conference Paper |
Times cited : (7)
|
References (13)
|